Last €2.97 EUR
Change Today -0.159 / -5.08%
Volume 0.0
RN3 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:17 PM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

arena pharmaceuticals inc (RN3) Snapshot

Open
€3.17
Previous Close
€3.13
Day High
€3.17
Day Low
€2.96
52 Week High
02/14/14 - €5.89
52 Week Low
10/14/14 - €2.62
Market Cap
654.6M
Average Volume 10 Days
195.0
EPS TTM
--
Shares Outstanding
220.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARENA PHARMACEUTICALS INC (RN3)

arena pharmaceuticals inc (RN3) Related Businessweek News

View More BusinessWeek News

arena pharmaceuticals inc (RN3) Details

Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Its products under development include APD811, an agonist of the prostacyclin receptor, which has completed single- and multiple-ascending dose Phase I trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials. The company’s products under development also comprise APD334, an agonist of the sphingosine 1-phosphate subtype 1 receptor for the treatment of conditions related to autoimmune diseases, which has completed Phase I single-ascending dose trial; and APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. It also manufactures drug products under a manufacturing services agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.

310 Employees
Last Reported Date: 03/3/14
Founded in 1997

arena pharmaceuticals inc (RN3) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $725.0K
Co-Founder, Executive Vice President, Chief S...
Total Annual Compensation: $420.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $360.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $395.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $375.0K
Compensation as of Fiscal Year 2013.

arena pharmaceuticals inc (RN3) Key Developments

Arena Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 08:30 AM

Arena Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 08:30 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

Arena Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter of 2014

Arena Pharmaceuticals, Inc. reported earnings results for the third quarter of 2014. For the quarter, the company reported loss of $10.7 million. The company had a loss of 5 cents per share. The company posted revenue of $8.2 million in the period.

Arena Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended Sept. 30, 2014

Arena Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended Sept. 30, 2014. The company posted loss of $10.7 million, or $0.05 diluted per share, compared with the prior-year period's $17.2 million or $0.08 diluted loss per share. Revenue was $8.16 million, up from $3.58 million in the same quarter last year. For the nine months, the company reported total revenues were $27.78 million against $74.88 million a year ago. Net loss was $28.45 million or $0.13 diluted loss per share against net income of $4.02 million or $0.02 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RN3:GR €2.97 EUR -0.159

RN3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $6.94 USD +0.13
Array BioPharma Inc $4.75 USD +0.11
Progenics Pharmaceuticals Inc $7.17 USD +0.18
Rigel Pharmaceuticals Inc $2.29 USD +0.07
Spectrum Pharmaceuticals Inc $7.03 USD +0.13
View Industry Companies
 

Industry Analysis

RN3

Industry Average

Valuation RN3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.9x
Price/Book 10.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARENA PHARMACEUTICALS INC, please visit www.arenapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.